Resultados globales: 3 registros encontrados en 0.02 segundos.
Artículos, Encontrados 3 registros
Artículos Encontrados 3 registros  
1.
13 p, 1.0 MB Adaptive Pathways : Possible Next Steps for Payers in Preparation for Their Potential Implementation / Vella Bonanno, Patricia (Department of Pharmacoepidemiology, Strathclyde Institute of Pharmacy and Biomedical Sciences, University of Strathclyde) ; Ermisch, Michael (Pharmaceutical Department, National Association of Statutory Health Insurance Funds) ; Godman, Brian (Division of Clinical Pharmacology, Karolinska Institutet) ; Martin, Antony P. (Health Economics Centre, University of Liverpool Management School) ; Van Den Bergh, Jesper (Department of Health) ; Bezmelnitsyna, Liudmila (National Research Institution for Public Health) ; Bucsics, Anna (Mechanism of Coordinated Access to Orphan Medicinal Products (MoCA)) ; Arickx, Francis (Department of Pharmaceutical Policy, National Institute for Health and Disability Insurance) ; Bybau, Alexander (Zilveren Kruis Achmea) ; Bochenek, Tomasz (Department of Drug Management, Faculty of Health Sciences, Jagiellonian University Medical College) ; van de Casteele, Marc (Department of Pharmaceutical Policy, National Institute for Health and Disability Insurance) ; Diogène Fadini, Eduard (Hospital Universitari Vall d'Hebron) ; Eriksson, Irene (Department of Medicine Solna, Karolinska Institutet) ; Fürst, Jurij (Medicinal Products Department, Health Insurance Institute of Slovenia) ; Gad, Mohamed (Global Health and Development Group, Imperial College) ; Greičiūtė-Kuprijanov, Ieva (Department of Pharmacy, Ministry of Health of the Republic of Lithuania) ; van der Graaff, Martin (National Health Care Institute (ZIN)) ; Gulbinovic, Jolanta (State Medicines Control Agency) ; Jones, Jan (Scottish Medicines Consortium) ; Joppi, Roberta (Clinical Research and Drug Assessment Unit) ; Kalaba, Marija (Pediatric Cardiology, Primary Healthcare Centre "Zemun") ; Laius, Ott (Department of Post-authorisation Safety, State Agency of Medicines) ; Langner, Irene (Wissenschaftliches Institut der AOK) ; Mardare, Ileana (Faculty of Medicine, Public Health and Management Department, "Carol Davila" University of Medicine and Pharmacy Bucharest) ; Markovic-Pekovic, Vanda (Department of Social Pharmacy, Medical Faculty, University of Banja Luka) ; Magnusson, Einar (Department of Health Services, Ministry of Health) ; Melien, Oyvind (Norwegian Directorate for Health) ; Meshkov, Dmitry O. (Department of Health) ; Petrova, Guenka I. (Department of Social Pharmacy and Pharmacoeconomics, Faculty of Pharmacy, Medical University of Sofia) ; Selke, Gisbert (Wissenschaftliches Institut der AOK) ; Sermet, Catherine (Institut de Recherche et Documentation en Economie de la Santé (IRDES)) ; Simoens, Steven (KU Leuven Department of Pharmaceutical and Pharmacological Sciences) ; Schuurman, Ad (National Health Care Institute (ZIN)) ; Ramos, Ricardo (Health Technology Assessment, Pricing and Reimbursement Department, Central Administration of the Health System, National Authority of Medicines and Health Products (I.P., INFARMED)) ; Rodrigues, Jorge (Health Technology Assessment, Pricing and Reimbursement Department, Central Administration of the Health System, National Authority of Medicines and Health Products (I.P., INFARMED)) ; Zara, Corinne (Barcelona Health Region, Catalan Health Service) ; Zebedin-Brandl, Eva (Department of Pharmaceutical Affairs, Main Association of Austrian Social Insurance Institutions) ; Haycox, Alan (Health Economics Centre, University of Liverpool Management School) ; Universitat Autònoma de Barcelona
Medicines receiving a conditional marketing authorization through Medicines Adaptive Pathways to Patients (MAPPs) will be a challenge for payers. The "introduction" of MAPPs is already seen by the European Medicines Agency (EMA) as a fait accompli, with payers not consulted or involved. [...]
2017 - 10.3389/fphar.2017.00497
Frontiers in Pharmacology, Vol. 8 (august 2017)  
2.
11 p, 1.1 MB Dabigatran - a continuing exemplar case history demonstrating the need for comprehensive models to optimize the utilization of new drugs / Godman, Brian (University of Strathclyde) ; Malmström, Rickard E. (Karolinska University Hospital Solna) ; Diogène Fadini, Eduard (Hospital Universitari Vall d'Hebron) ; Jayathissa, Sisira (Hutt Valley DHB. Department of Medicine) ; McTaggart, Stuart (NHS National Services Scotland) ; Cars, Thomas (Uppsala University. Department of Medical Sciences) ; Alvarez-Madrazo, Samantha (University of Strathclyde) ; Baumgärtel, Christoph (Austrian Medicines and Medical Devices Agency) ; Brzezinska, Anna (Agency for Health Technology Assessment) ; Bucsics, Anna (Hauptverband der Österreichischen Sozialversicherungsträger) ; Campbell, Stephen (University of Manchester. Centre for Primary Care) ; Eriksson, Irene (Stockholm County Council. Department of Healthcare Development) ; Finlayson, Alexander (University of Oxford. Green Templeton College) ; Fürst, Jurij (Health Insurance Institute) ; Garuoliene, Kristina (National Health Insurance Fund) ; Gutiérrez-Ibarluzea, Iñaki (Osasun Saila. Ezagutu Osteba arloa) ; Hviding, Krystyna (Norwegian Medicines Agency) ; Herholz, Harald (Kassenärztliche Vereinigung Hessen) ; Joppi, Roberta (Azienda Sanitaria Locale of Verona. Pharmaceutical Drug Department) ; Kalaba, Marija (Republic Institute for Health. Department of Medicines and Pharmacoeconomics) ; Laius, Ott (State Agency of Medicines) ; Malinowska, Kamila (National Health Fund. Drug Management Department) ; Pedersen, Hanne B. (Division of Health Systems and Public Health, Health Technologies and Pharmaceuticals, WHO Regional Office for Europe) ; Markovic-Pekovic, Vanda (Ministry of Health and Social Welfare) ; Piessnegger, Jutta (Hauptverband der Österreichischen Sozialversicherungsträger) ; Selke, Gisbert (Wissenschaftliches Institut der AOK (WidO)) ; Sermet, Catherine (IRDES) ; Spillane, Susan (Trinity College. Department of Pharmacology and Therapeutics) ; Tomek, Dominik (Slovak Medical University. Faculty of Pharmacy) ; Vončina, Luka (Ministry of Health) ; Vlahović-Palčevski, Vera (University Hospital Rijeka. Unit for Clinical Pharmacology) ; Wale, Janet (Independent Consumer Advocate, VIC) ; Wladysiuk, Magdalena (HTA Consulting) ; van Woerkom, Menno (Dutch Institute for Rational Use of Medicine) ; Zara, Corinne (Institut Català de la Salut) ; Gustafsson, Lars L. (Karolinska University Hospital Huddinge) ; Universitat Autònoma de Barcelona
Background : There are potential conflicts between authorities and companies to fund new premium priced drugs especially where there are effectiveness, safety and/or budget concerns. Dabigatran, a new oral anticoagulant for the prevention of stroke in patients with non-valvular atrial fibrillation (AF), exemplifies this issue. [...]
2014 - 10.3389/fphar.2014.00109
Frontiers in Pharmacology, Vol. 5 (june 2014)  
3.
8 p, 147.9 KB Benchmarking en la atención primaria de salud : una estrategia de mejora de la calidad / Plaza, Aina ; Guarga, Àlex ; Zara, Corinne ; Ruano, Ignasi
La administración sanitaria inició en el año 1993 el proceso sistemático de evaluación de los EAP. Una vez finalizada la reforma de la atención primaria (RAP) en la ciudad de Barcelona, el Consorci Sanitari de Barcelona (CSB) se propone enfatizar en la publicación de los resultados de la evaluación de los EAP como una parte substancial de las dinámicas de gestión de la calidad y de trasparencia de los resultados de los servicios sanitarios públicos. [...]
2005
Revista clínica electrónica en atención primaria, Núm. 7 (Juny 2005) , p. 1-8  

¿Le interesa recibir alertas sobre nuevos resultados de esta búsqueda?
Defina una alerta personal vía correo electrónico o subscríbase al canal RSS.